LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

Certara to Participate in Upcoming Investor Conferences

August 21, 2024 | Last Trade: US$9.96 0.57 -5.41

RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

  • Morgan Stanley 22nd Annual Global Healthcare Conference
    Date and Time: Wednesday, September 4 at 4:05 p.m. ET
  • Baird Global Healthcare Conference
    Date and Time: Wednesday, September 11 at 10:15 a.m. ET

Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Alyssa Horowitz
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB